CL2022003534A1 - Combinación de alcaftadina y un corticoesteroide - Google Patents

Combinación de alcaftadina y un corticoesteroide

Info

Publication number
CL2022003534A1
CL2022003534A1 CL2022003534A CL2022003534A CL2022003534A1 CL 2022003534 A1 CL2022003534 A1 CL 2022003534A1 CL 2022003534 A CL2022003534 A CL 2022003534A CL 2022003534 A CL2022003534 A CL 2022003534A CL 2022003534 A1 CL2022003534 A1 CL 2022003534A1
Authority
CL
Chile
Prior art keywords
alcaftadine
corticosteroid
pharmaceutically acceptable
acceptable salt
combination
Prior art date
Application number
CL2022003534A
Other languages
English (en)
Inventor
Ulhas Dhuppad
Akhilesh Sharma
Babasaheb Aware
Viraj Shah
Amol Aiwale
Original Assignee
Alkem Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkem Laboratories Ltd filed Critical Alkem Laboratories Ltd
Publication of CL2022003534A1 publication Critical patent/CL2022003534A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica tópica que comprende alcaftadina o una sal farmacéuticamente aceptable de esta y un corticoesteroide o una sal farmacéuticamente aceptable de este, a los métodos para tratar la rinitis alérgica, la rinoconjuntivitis alérgica o síntomas de estas (tales como la congestión nasal) con una combinación de alcaftadina o una sal farmacéuticamente aceptable de esta y un corticoesteroide o una sal farmacéuticamente aceptable de este y a los métodos para preparar la composición tópica.
CL2022003534A 2020-06-15 2022-12-12 Combinación de alcaftadina y un corticoesteroide CL2022003534A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201921053286 2020-06-15

Publications (1)

Publication Number Publication Date
CL2022003534A1 true CL2022003534A1 (es) 2023-06-23

Family

ID=76523259

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003534A CL2022003534A1 (es) 2020-06-15 2022-12-12 Combinación de alcaftadina y un corticoesteroide

Country Status (12)

Country Link
US (1) US20230218630A1 (es)
EP (1) EP4164614A1 (es)
JP (1) JP2023530166A (es)
KR (1) KR20230024928A (es)
CN (1) CN115701988A (es)
AU (1) AU2021291684A1 (es)
BR (1) BR112022024840A2 (es)
CA (1) CA3181959A1 (es)
CL (1) CL2022003534A1 (es)
MX (1) MX2022015965A (es)
WO (1) WO2021255622A1 (es)
ZA (1) ZA202212128B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
JP2024512121A (ja) * 2021-04-01 2024-03-18 アルケム・ラボラトリーズ・リミテッド アルカフタジンを含む鼻用組成物
WO2023133460A1 (en) * 2022-01-06 2023-07-13 Cyrano Therapeutics, Inc. Improved nasal administration of pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053678T3 (es) 1987-11-13 1994-08-01 Asta Medica Ag Procedimiento para preparar un medicamento con contenido de azelastina para la aplicacion nasal y/u ocular.
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv History 11-) 4-Pipridinyl (-Imidazo] B-1, 2 [] 3 [Benzazepine, their preparation and pharmaceutical preparations containing them
SI1919450T1 (sl) 2005-09-01 2014-10-30 Meda Ab Liposomski sestavek, ki vsebuje antihistaminik in kortikosteroid, in njegova uporaba za izdelavo zdravila za zdravljenje rinitisa in sorodnih motenj
EA016221B1 (ru) * 2006-03-31 2012-03-30 ВИСТЭКОН ФАРМАСЬЮТИКАЛС, ЭлЭлСи Офтальмические композиции и способ лечения аллергических заболеваний глаз
WO2011141929A2 (en) * 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
CN102283849A (zh) 2011-06-29 2011-12-21 北京阜康仁生物制药科技有限公司 一种含有阿卡他定的药物组合物
HUE056448T2 (hu) * 2013-09-13 2022-02-28 Glenmark Specialty Sa Stabil, rögzített adagolású gyógyszerkészítmény, amely mometazont és olopatadint tartalmaz orrba történõ beadásra
WO2019022225A1 (ja) 2017-07-28 2019-01-31 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物

Also Published As

Publication number Publication date
ZA202212128B (en) 2024-04-24
CA3181959A1 (en) 2021-12-23
MX2022015965A (es) 2023-03-14
CN115701988A (zh) 2023-02-14
US20230218630A1 (en) 2023-07-13
BR112022024840A2 (pt) 2022-12-27
EP4164614A1 (en) 2023-04-19
KR20230024928A (ko) 2023-02-21
AU2021291684A1 (en) 2022-12-08
JP2023530166A (ja) 2023-07-13
WO2021255622A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
CL2022003534A1 (es) Combinación de alcaftadina y un corticoesteroide
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CR20160327A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2014000122A1 (es) Compuestos derivados de indazol, inhibidores de janus quinasa (jak); composicion farmaceutica que los comprende; y su uso para tratar rinitis alergica, congestion nasal, asma, bronquitis cronica, artritis, insuficiencia cardiaca, colitis ulcerativa, infeccion viral y bacteriana, cancer y alzheimer, entre otras enfermedades.
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112018068532A2 (pt) combinações de inibidores de lsd1 para o tratamento de malignidades hematológicas
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112018005861A2 (pt) derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos
EA201692278A1 (ru) Комбинации формотерола и будесонида для лечения хобл
CL2017001913A1 (es) Composición tópica curativa
CL2023002871A1 (es) Composiciones nasales que comprenden alcaftadina
TR201000622A2 (tr) Tiotropyum içeren farmasötik kombinasyonlar.
CO2018010951A2 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
CO2021001174A2 (es) Inhibidores de ckd8/19
BR112019005578A2 (pt) compostos de indazol para uso em lesões no tendão e/ou ligamento
EA202193343A1 (ru) Вдыхаемая композиция, содержащая циклодекстрин, для применения при лечении назальных воспалений
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos
BR112015025033A8 (pt) Prodrogas de inibidores da pde-5 do tipo pirimidina bicíclica substituída
MX2015003937A (es) Composicion farmaceutica de antihistaminico no sedante e inmunosupresor antiinflamatorio.
BR112015017541A2 (pt) fármaco profilático ou terapêutico para constipação